Ainos reports FY2024 revenue $20,729, net loss $14.9M; AI Nose and VELDONA progress

Ainos, Inc.

Revenue fell 83% YoY to $20,729; cost of revenues $52,595; gross loss narrowed to $31,866.
Net loss attributable to common shareholders $14.86M vs $13.77M in FY2023.
Cash and equivalents $3.89M as of Dec 31, 2024, up from $1.89M a year ago.
R&D expenses rose to $8.4M (including share-based comp); SG&A decreased to $5.4M.
Key milestones: AI Nose Flora second-gen clinical studies H1 2025; VELDONA Japan patent and Taiwan Tanabe partnership; IRB approval for Sjögren's trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.